Could simvastatin be a treatment for secondary progressive MS?

Dr Jeremy Chataway

UCL Institute of Neurology

£3.82M in partnership with NIHR and National MS Society.

Additional support from UCL and the NHS

 

About the project

We’re proud to be co-funding the phase 3 trial testing if simvastatin can slow progression in secondary progressive MS. If successful, simvastatin could be of the first treatments licensed for this type of MS.

The MS-STAT2 trial will test if simvastatin can slow disability progression over a three-year period. They will measure progression using the Expanded Disability Status Scale, which assesses changes in walking and other MS symptoms.

The trial began in summer 2017 and will involve 1,180 people with secondary progressive MS. It will take six years to complete and involve over 30 trial centres across the UK.

>> Sign up to hear when recruitment starts

How will it help people with MS?

Right now there are no treatments that can slow or stop the accumulation of disability associated with MS. If this trial is successful, simvastatin could be one of the first treatments licensed for secondary progressive MS.

The difference you can make

The race is on to find therapies that will slow progression. You can help speed up the process by supporting projects like this.

>> Donate now to fund MS research

The next research breakthrough is within reach

Donate now

What's new?